基本信息
浏览量:22
职业迁徙
个人简介
Research interest
We investigate immunoregulatory mechanisms to identify biomarkers of immune disease and targets for immunotherapy. Our focus is on type 1 diabetes (T1D) as a paradigm for the pre-clinical diagnosis, prediction and prevention of autoimmune disease; we also study immune-inflammatory mechanisms in type 2 diabetes (T2D).
After demonstrating the primacy of insulin as an autoantigen driving pancreatic beta-cell destruction in T1D, and its application as a therapeutic tool to induce regulatory anti-diabetogenic T cells, we have conducted a series of trials to determine if a nasal insulin vaccine will prevent T1D in humans. To better understand environment-gene interactions in T1D we are undertaking microbiome, metabolome, epigenome and immunome studies of mothers during pregnancy and their T1D at-risk infants though early life.
Recently, we described a novel immunoregulatory mechanism whereby soluble CD52, released from activated T cells, suppresses other T cells and innate immune cells via Siglec receptor pathways. The therapeutic potential of CD52-Fc is being investigated.
We investigate immunoregulatory mechanisms to identify biomarkers of immune disease and targets for immunotherapy. Our focus is on type 1 diabetes (T1D) as a paradigm for the pre-clinical diagnosis, prediction and prevention of autoimmune disease; we also study immune-inflammatory mechanisms in type 2 diabetes (T2D).
After demonstrating the primacy of insulin as an autoantigen driving pancreatic beta-cell destruction in T1D, and its application as a therapeutic tool to induce regulatory anti-diabetogenic T cells, we have conducted a series of trials to determine if a nasal insulin vaccine will prevent T1D in humans. To better understand environment-gene interactions in T1D we are undertaking microbiome, metabolome, epigenome and immunome studies of mothers during pregnancy and their T1D at-risk infants though early life.
Recently, we described a novel immunoregulatory mechanism whereby soluble CD52, released from activated T cells, suppresses other T cells and innate immune cells via Siglec receptor pathways. The therapeutic potential of CD52-Fc is being investigated.
研究兴趣
论文共 586 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Diabetes technology & therapeuticsno. 2 (2024): 87-94
R. L. Thomson, J. D. Brown, H. Oakey, M. A. S. Penno, R. Battersby, P. Ashwood, G. Soldatos, P. G. Colman, M. E. Craig,E. A. Davis,M. Harris.,L. C. Harrison,
引用0浏览0引用
0
0
Jessica G Borger, Ashley P Ng, Holly Anderton, George W Ashdown, Megan Auld,Marnie E Blewitt, Daniel V Brown,Melissa J Call, Peter Collins,Saskia Freytag,Leonard C Harrison, Eva Hesping,
Annals of Medicineno. 1 (2023): 2198255-2198255
Leonard C. Harrison,Esther Bandala-Sanchez,Helena Oakey,Peter G. Colman,Kelly Watson,Ki Wook Kim, Roy Wu, Emma E. Hamilton-Williams,Natalie L. Stone,Aveni Haynes,Rebecca L. Thomson,Peter J. Vuillermin,
Journal of Diabetes Investigationno. 9 (2023): 1092-1100
EUROPEAN RESPIRATORY JOURNAL (2023)
The Journal of allergy and clinical immunologyno. 3 (2023): 667-675
Michaela Waibel,John M Wentworth,Michelle So,Jennifer J Couper,Fergus J Cameron,Richard J MacIsaac, Gabby Atlas, Alexandra Gorelik,Sara Litwak,Laura Sanz-Villanueva,Prerak Trivedi, Simi Ahmed,
The New England journal of medicineno. 23 (2023): 2140-2150
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn